Healthcare and consumer products giant Johnson & Johnson (JNJ) is likely to report first-quarter results before the bell on Tuesday, April 19. JNJ is expected to show a small improvement in first quarter results, compared to the year-ago period with analysts estimating earnings of $1.66 per share on revenue of $17.50 billion. Analysts' estimate typically exclude certain special items. The company is likely to beat earnings estimates by a low single digit percentage.
Potential sales catalysts include* DARZALEX for treating double refractory multiple myeloma * YONDELIS for the treatment of patients with unresectable or metastatic liposarcoma or leiomyosarcomaBoth drugs were approved in the fourth quarter.* European Commission approval of EDURANT in combination with other anti-retroviral agents, for treatment-naïve adolescent patients aged 12 to 18 years with HIV-1 infection. (Approved in the fourth quarter)* Rich near-term pipeline* A full portfolio of OTCs back on the market
For fiscal 2016, the company expects sales to be in the range of $70.8 billion - $71.5 billion, reflecting expected operational growth in the range of 2.5% - 3.5%. Excluding the impact of acquisitions, divestitures and hepatitis C sales, operational sales growth is expected to be in the range of 4.5% - 6.0%.
Additionally, the company sees 2016 adjusted earnings between $6.43 and $6.58 per share, reflecting expected operational growth in the range of 5.3% - 7.7%. Wall Street analysts have a consensus earnings estimate of $6.53 per share and revenue of $71.55 billion for 2016.
In the last quarter...
Net earnings for the fourth quarter of 2015 increased to $3.22 billion or $1.15 per share from $2.52 billion or $0.89 per share in the fourth-quarter 2014.
Adjusted net earnings for the quarter rose to $4.04 billion or $1.44 per share from $3.89 billion or $1.37 per share in the prior year. On an operational basis, adjusted earnings per share increased 12.4% to $1.54 from the prior year.
Sales were $17.8 billion for the fourth quarter of 2015, a decrease of 2.4% as compared to the fourth quarter of 2014. Operational sales results increased 4.4% and the negative impact of currency was 6.8%. Domestic sales increased 8.0%.
International sales decreased 11.7%, reflecting operational growth of 1.2% and a negative currency impact of 12.9%. Excluding the net impact of acquisitions, divestitures and hepatitis C sales, on an operational basis, worldwide sales increased 7.8%, domestic sales increased 13.4% and international sales increased 2.9%.
Alex Gorsky, Chairman and Chief Executive Officer, said, "Johnson & Johnson delivered strong underlying growth in 2015, driven by the performance of our Pharmaceutical business and iconic Consumer brands. As we enter 2016, our core business is very healthy, and the recent decisive actions we've taken in support of each of our businesses position us well to drive sustainable long-term growth, faster than the markets we compete in."
For comments and feedback contact: editorial@rttnews.com
Business News
May 15, 2026 15:25 ET Apart from the confirmation of Kevin Warsh as the next Fed chair, the main news on the economics front this week included key price data from the U.S. and the first quarter economic growth figures from major economies. Both consumer prices and producer costs have started to reflect the effect of supply shocks due to the Middle East conflict. In Europe, GDP data was in focus, while inflation data from China dominated the news flow in Asia.